You are here: NGED > Research Portfolio - Members

Network Member Profile

Current Field of Study

• Skeletal muscle damage and repair and therapies for muscular dystrophy

Australian Collaborators

• Dr Greg Harper, MLA/CSIRO, Queensland.
• Dr Jason White, Melbourne Uni, Victoria
• Dr Marie Dziadek, Garvan, Sydney, NSW
• A/Prof Gordon Lynch, Melbourne Uni. Victoria
• A/Prof Marie Bogoyevitch, Melbourne Uni, Victoria
  
  

International Collaborators

• Prof Ulla Wewer, Uni Copengahan, Denmark
• Profs Lydia Sorokin & Rupert Hallmann, Uni of Muenster, Germany
• Various others in Paris and the USA
  
  

Facilities

CellCentral

Recent Publications

1. Grounds MD, Radley H, Gbeski B, Bogoyevitch, M, Shavlakadze TS. (2007) Implications of cross-talk between TNF? and IGF-1 signalling in skeletal muscle. Clinical and Experimental Pharmacology and Physiology. Accepted for publication.

2. Grounds MD, Davies. (2007) The allure of stem cell therapy for muscular dystrophy. Neuromuscular Disorders Mar;17(3):206-8.

3. Radley H, De Luca A, Lynch GS, Grounds MD. (2007) Duchenne Muscular Dystrophy: focus on pharmaceutical and nutritional interventions. Internat. J. Biochem. Cell Biology. 39(3):469-77.

4. Davies K, Grounds MD (2006) Treating muscular dystrophy with stem cells? Cell. Dec 29, 127 (7):1304-6.

5. Shavlakadze T, Grounds MD. (2006) Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. BioEssays. 28(10): 994-1009.

6. Hodgetts S, Radley H, Davies M, Grounds MD. (2006) Reduced necrosis of dystrophic muscle by depletion of host neutrophils or blockading TNF function with Etanercept in mdx mice. Neuromuscular Disorders. Oct;16(9-10):591-602.

7. Han R, Grounds MD, Bakker AJ. (2006) Measurement of sub-membrane [Ca2+] in adult myofibers and cytosolic [Ca2+] in myotubes from normal and mdx mice using the Ca2+ indicator FFP-18. Cell Calcium. Sep;40(3):299-307

8. Radley H, Grounds MD. (2006) Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiology of Disease. Aug;23(2):387-97.

9. Shavlakadze T, White JD, Davies M, Grounds MD, Boswell JM, Burt DW, Asante EA, Tomas FM, Goddard C. (2006) Rsk?-actin/hIGF-I transgenic mice with increased IGF-I levels in skeletal muscle and blood: impact on regeneration, denervation, atrophy and muscular dystrophy. Growth Hormone and IGF Research Jun;16(3):157-73.

10. Shavlakadze T, Rosenthal NA, Wynn N, Grounds MD. (2005) Reconciling data from transgenic mice that over-express IGF-1 specifically in skeletal muscle Growth Hormone and IGF Research. 15: 4-18.

11. Shavlakadze T, White J, Davies M, Hoh JYF, Grounds MD. (2005) Insulin-like growth factor-1 slows the rate of denervation induced skeletal muscle atrophy. Neuromuscular Disorders. 15: 139-146.

12. Lynch G, Shavlakadze T, Grounds MD. (2005) Evaluation of strategies to reduce age-related skeletal muscle wasting. In: Ageing Interventions and Therapies (Ed, Rattan SIS) World Scientific Publishers, Singapore. Chapter 4. pp 63-84.

13. Grounds MD, Davies M, Torrisi J, Shavlakadze J, Hodgetts S. (2005) Silencing TNF activity using Remicade® or Enbrel® blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Cell and Tissue Research. 320(3):509-15.

14. Grounds MD, Sorokin L, White J. (2005) Strength at the extracellular-muscle interface. Scandinavian Journal of Medicine & Science in Sports. Dec;15(6):381-91.

15. Pullen TP & Grounds MD (2005) The reality of skeletal muscle stem cells. Australian Biochemist. April. 26(1): 4-6.

16. Lee-Pullen T, Grounds MD. (2005) Muscle derived stem cells; implications for effective myoblast transfer therapy. (International Union of Biochemistry and Molecular Biology) IUBMB Life. 57(11):731-736.

17. Grounds MD, Torrisi J (2004) Anti-TNF? (Remicade®) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 18: 676-682.

18. Lloyd CM, Berendse M, Lloyd DG, Schevzov G, Grounds MD. (2004) A novel role for non-muscle ?-actin in skeletal muscle sarcomere assembly. Experimental Cell Research. 297:82-96

19. Sammels L, Bosio E, Fragall CT, Grounds MD, van Rooijen N, Beilharz MW. (2004). Innate inflammatory cells are not responsible for early death of donor myoblasts following Myoblast Transfer Therapy. Transplantation. 77 (12):1790-1797.

20. Lee-Pullen TF, Bennett A, Beilharz MW, Grounds MD, Sammels LM. (2004) Superior survival and proliferation following transplantation of myoblasts obtained from adult mice compared to neonatal mice. Transplantation. Oct 27;78(8):1172-6.

21. Shavlakadze T, White JD, Davies M, Grounds MD. (2004) Early regeneration of whole skeletal muscle grafts is unaffected by over-expression of IGF-1 in MLC/mIGF-1 transgenic mice. J. Histochem Cytochem. 52:873-883.

22. Shavlakadze T, White J, Rosenthal NA, Grounds MD. (2004) Targeted expression of insulin-like growth factor-I reduces the necrosis of dystrophic mdx muscle. Molecular Therapy. Nov;10(5):829-43.

23. Grounds MD (2004). Discussion: Reconstruction of Ablated Rat Rectus Abdominis by Muscle Regeneration Plastic and Reconstructive Surgery. 114(6):1516-1518

24. Bosio E, Lee-Pullen TF, Fragall CT, Beilharz MW, Bennettt AL, Grounds MD, Hodgetts SI, Sammels LM. (2004) A comparison between real time quantitative PCR and DNA hybridisation for quantification of male donor cell survival following myoblast transplantation. Cell Transplantation. 13(7 8), pp. 817-821.

25. Hodgetts SI, Spencer MJ, Grounds MD. (2003) A role for Natural Killer cells in the rapid death of cultured donor myoblasts after transplantation. Transplantation 75 (6): 863-871.

26. White J, Grounds MD (2003) Harnessing the therapeutic potential of myogenic stem cells. (Invited review). Cytotechnology. 41:153-164.

27. Shavlakadze T, Grounds MD (2003) Therapeutic interventions for age-related muscle wasting: importance of innervation and exercise for preventing sarcopenia. Chapter in 'Modulating aging and longevity'. Series on Biology of Ageing and its modulation. uwer Academic Publisher, the Netherlands. Series Editor: Suresh Rattan). Volume 5: Chapter 9, pp139-166.

28. Han R, Suizu T, Grounds M, Bakker AJ. (2003) Effect of indomethacin on force responses and sarcoplasmic reticulum function in skinned skeletal muscle fibres and cytosolic [Ca2+] in myotubes. American Journal of Physiology Cell Physiology. Oct;285(4):C881-C890.

29. Hodgetts SI and Grounds MD. (2003) Irradiation of dystrophic host tissue prior to Myoblast Transfer Therapy enhances initial (but not long-term) survival of donor myoblasts. J. Cell Science Oct 15;116(Pt 20):4131-4146

30. Berendse M, Grounds MD, Lloyd CM. (2003) Myoblast structure affects subsequent skeletal myotube morphology and sarcomere assembly. Exp. Cell Res. 291: 435-50.

31. Grounds MD (2002) Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology. 3: 19-24.

32. Hamer PW, McGeachie JM, Davies MJ, Grounds MD. (2002) Evans Blue Dye as an in vivo marker of myofibre fragility and damage: Optomising parameters for detecting initial myofibre permeability. J Anatomy. 200(1):69-79.

33. White JD, Collins R, Vermeulen R, Davies M, Grounds MD (2002) The role of p53 in vivo during skeletal muscle post-natal development and regeneration: studies in p53 knockout mice. International J. Develop. Biol. 46: 577-582.

34. Grounds MD, White J, Rosenthal N, Bogoyevitch M. (2002) The role of stem cells in Skeletal and Cardiac Muscle repair. J Histochem. Cytochem. 50: 589-610.

35. Smythe GM, Lai M-C, Grounds MD, Rakoczy P. (2002) Adeno-associated virus-mediated transfer of vascular endothelial growth factor in skeletal muscle prior to transplantation promotes revascularisation of the regenerating skeletal muscle. Tissue Engineering 8(5): 879-891.

36. White JD, Davies M, McGeachie J, Grounds MD. (2002). An evaluation of Leukaemia Inhibitory Factor as a potential therapeutic agent for the treatment of muscle disease. Neuromuscular Disorders. 12(10): 909-916.

37. Hodgetts SI and Grounds MD. (2001) Complement and myoblast transfer therapy: Donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5. Immunology and Cell Biology. 79 (3): 231-239.

38. Smythe G, Davies M, Paulin D, Grounds M. (2001) Absence of desmin slightly prolongs myoblast differentiation and delays fusion in vivo in regenerating grafts of skeletal muscle. Cell & Tissue Research. 304:287-294.

39. Smythe G, Hodgetts S, Grounds MD (2001) Problems and solutions in myoblast transfer therapy. Invited review. J. Cell. Mol. Medicine. 5(1):33-47.

40. Collins RA, Grounds MD. (2001) The role of Tumour Necrosis Factor-alpha (TNF ) in muscle regeneration: Studies in TNF (-/-) and TNF (-/-) /LT (-/-) mice. J. Histochem. Cytochem. 49:1-13 .

41. Huijbregts J, White JD and Grounds MD. (2001) The absence of MyoD in regenerating skeletal muscle affects the expression pattern of basement membrane, interstitial matrix and integrin molecules that is consistent with delayed myotube formation. Acta Histochemica. 103(4): 379-96.

42. Smythe G, Grounds MD. (2001) Absence of MyoD increases donor myoblast migration into host muscle. Experimental Cell Research. 267:267-274.

43. White JD, Davies M, Grounds MD. (2001) Leukaemia Inhibitory Factor increases myoblast replication and survival and affects extracellular matrix production: combined in vitro and in vivo studies in post-natal skeletal muscle. Cell and Tissue Research. 306:129-141.

44. Smythe G., Fan Y, Grounds MD (2000). Enhanced migration and fusion of donor myoblasts in dystrophic and normal host muscle. Muscle & Nerve. 23(4):560-574.

45. Smythe GM, Grounds MD (2000). Exposure to tissue culture conditions can adversely affect myoblast behaviour in vivo in whole muscle grafts: implications for myoblast transfer therapy. Cell Transplantation. 9(3):379-393.

46. Smythe GM, Hodgetts SI, Grounds MD. (2000) Immunobiology and the future of Myoblast Transfer Therapy. Molecular Therapy. 1(4): 304 -313.

47. Sorokin LM, Maley MAL, Moch H, von der Mark H, von der Mark K, Cadalbert L, Karosi S, Davies MJ, McGeachie JK, Grounds MD. (2000) Laminin 4 and integrin 6 are upregulated in regenerating dy/dy skeletal muscle: comparative expression of laminin and integrin isoforms in muscles regenerating after crush injury. Exp. Cell Research. 256: 500-514.

48. Hodgetts SI, Beilharz MW, Scalzo AA, Grounds MD (2000). Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ or NK1.1+ cells. Cell Transplantation. 9(4): 489-502.

49. Grounds MD. (2000) Myoblast transfer therapy in the new Millenium: Commentary. Cell Transplantation. 9(4): 485-487.

50. White J, Scaffidi A, McGeachie JM, Davies M, Rudnicki M, Grounds MD. (2000) Myotube formation is delayed but not prevented in MyoD deficient skeletal muscle: studies in regenerating whole muscle grafts of adult mice. J. Histochem. Cytochem. 48(11): 1531-1544.